Commentary

Video

Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer

Author(s):

Angeles Alvarez Secord, MD

Fact checked by:

Ashling Wahner Kristi Rosa
Conference|ESMO Congress

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.

Related Videos
Andrea Wolf, MD, MPH
Nagashree Seetharamu, MD, MBBS
Shirish M. Gadgeel, MD
Shyam A. Patel, MD, PhD
Yuan Yuan, MD, PhD
Amitkumar Mehta, MD
Dingwei Ye, MD, PhD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Guillermo Garcia-Manero, MD
Related Content
Alexander Spira, MD, PhD, FACP
September 18th 2024

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Ana Oaknin, MD
September 18th 2024

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Xinan Sheng, MD, of Peking University Cancer Hospital and Institute
September 17th 2024

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

Nabil Saba, MD
September 17th 2024

Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma